Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
- DOI
- 10.1016/j.breast.2022.01.016
- Published
- 2022 Apr
- Container
- Breast (Edinburgh, Scotland)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.breast.2022.01.016,
title = {Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.},
author = {Cottu P and Ring A and Abdel-Razeq H and Marchetti P and Cardoso F and Salvador Bofill J and Martín M and Menon-Singh L and Wu J and De Laurentiis M},
year = {2022},
journal = {Breast (Edinburgh, Scotland)},
doi = {10.1016/j.breast.2022.01.016},
url = {https://doi.org/10.1016/j.breast.2022.01.016}
}RIS
TY - JOUR TI - Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial. AU - Cottu P AU - Ring A AU - Abdel-Razeq H AU - Marchetti P AU - Cardoso F AU - Salvador Bofill J AU - Martín M AU - Menon-Singh L AU - Wu J AU - De Laurentiis M PY - 2022 JO - Breast (Edinburgh, Scotland) DO - 10.1016/j.breast.2022.01.016 UR - https://doi.org/10.1016/j.breast.2022.01.016 ER -
APA
P, C., A, R., H, A., P, M., F, C., J, S. B., M, M., L, M., J, W., & M, D. L. (2022). Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2022.01.016
Source records
- pubmed · retrieved 2026-09-25T15:40:09.505Z